RYTM
RHYTHM PHARMACEUTICALS, INC.
Key Financials
Net Income
$-196539000
↑ 24.6%
Operating Income
$-192016000
↑ 27.7%
Revenue
$189.8M
↑ 45.8%
Shareholders' Equity
$139.1M
↑ 540.0%
Total Liabilities
$210.2M
↓ 7.7%
Total Assets
$480.2M
↑ 22.4%
Cash & Equivalents
$54.3M
↓ 39.1%
EPS (Diluted)
$-3.11
↑ 28.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/19/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| S-8 | 5/5/2026 | View on SEC |
| DEFA14A | 5/5/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| SCHEDULE 13G | 4/30/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEF 14A | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RYTM |
| Company Name | RHYTHM PHARMACEUTICALS, INC. |
| CIK | 1649904 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-264-4280 |